Prospective non-interventional BELOVA/BGOG-ov16 study on safety of frontline bevacizumab in elderly patients with FIGO stage IV ovarian cancer: a study of the Belgian and Luxembourg Gynaecological Oncology Group

Objective Because elderly patients with ovarian cancer are underrepresented in randomized studies, this study aimed to expand our knowledge on the safety and effectiveness of frontline treatment with bevacizumab in combination with standard carboplatin and paclitaxel chemotherapy in patients aged 70 years and older with a diagnosis of Federation of Gynecology and Obstetrics (FIGO) stage IV ovarian cancer in routine clinical practice in Belgium.Methods Patients aged 70 years and older with FIGO stage IV ovarian cancer were included in a multicenter, non-interventional prospective study to evalu... Mehr ...

Verfasser: Vergote, I
Van Nieuwenhuysen, E
De Waele, S
Vulsteke, C
Lamot, C
Van den Bulck, H
CLAES, Nele
Graas, MP
DEBROCK, Guy
Spoormans, I
Vuylsteke, P
Honhon, B
Verhoeven, D
Daan De Maeseneer
Dirix, L
MEBIS, Jeroen
Vroman, P
Denys, H
Mena, CM
Pelgrims, G
Van Steenberghe, M
van Gorp, T
Gennigens, C
Dokumenttyp: Artikel
Erscheinungsdatum: 2023
Verlag/Hrsg.: BMJ PUBLISHING GROUP
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-29107576
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : http://hdl.handle.net/1942/40403